Reinhard Bos

4.0k total citations · 2 hit papers
59 papers, 2.9k citations indexed

About

Reinhard Bos is a scholar working on Rheumatology, Immunology and Cancer Research. According to data from OpenAlex, Reinhard Bos has authored 59 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Rheumatology, 16 papers in Immunology and 11 papers in Cancer Research. Recurrent topics in Reinhard Bos's work include Rheumatoid Arthritis Research and Therapies (24 papers), Spondyloarthritis Studies and Treatments (22 papers) and Psoriasis: Treatment and Pathogenesis (12 papers). Reinhard Bos is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (24 papers), Spondyloarthritis Studies and Treatments (22 papers) and Psoriasis: Treatment and Pathogenesis (12 papers). Reinhard Bos collaborates with scholars based in Netherlands, United States and Germany. Reinhard Bos's co-authors include Elsken van der Wall, P. J. van Diest, Gregg L. Semenza, Petra van der Groep, Herbert M. Pinedo, Astrid E. Greijer, Avi Shvarts, Elisabeth Brouwer, P. J. van Diest and Haining Zhong and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Reinhard Bos

56 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Levels of Hypoxia-Inducible Factor-1 During Breast Carcinogenesis

2001 508 citations Reinhard Bos, Haining Zhong et al. JNCI Journal of the National Cancer Institute profile →
Levels of hypoxia‐inducible factor‐1α independently predict prognosis in patients with lymph node negative breast carcinoma

2003 413 citations Reinhard Bos, Petra van der Groep et al. profile →

Peers

Countries citing papers authored by Reinhard Bos

Since Specialization

Citations

This map shows the geographic impact of Reinhard Bos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reinhard Bos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reinhard Bos more than expected).

Fields of papers citing papers by Reinhard Bos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Reinhard Bos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reinhard Bos. The network helps show where Reinhard Bos may publish in the future.

Co-authorship network of co-authors of Reinhard Bos

This figure shows the co-authorship network connecting the top 25 collaborators of Reinhard Bos. A scholar is included among the top collaborators of Reinhard Bos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reinhard Bos. Reinhard Bos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Disease Acceptance and Control from the Subjective Health Experience Model as Health Perception Predictors in Immune-Mediated Inflammatory Diseases 2025 ·Biomedicines ·(unknown), (unknown), Robert M. Vodegel, Reinhard Bos, Greetje J. Tack	0
2	Interrelationships of disease activity, central sensitization, psychosocial and lifestyle factors in axial spondyloarthritis 2025 ·Lara D. Veeken ·(unknown), (unknown), Suzanne Arends, (unknown), Reinhard Bos, Roy E. Stewart, Davy Paap, Anneke Spoorenberg	0
3	Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial 2023 ·Annals of the Rheumatic Diseases ·(unknown), Maarten Boers, Linda Hartman, Daniela Opriș-Belinski, Reinhard Bos, Marc R. Kok, José António Pereira da Silva, E. N. Griep, Ruth Klaasen, Cornelia F Allaart, Paul Baudoin, Hennie G. Raterman, Zoltán Szekanecz, Frank Buttgereit, P. Masaryk, Willem F. Lems, Yvo M. Smulders, Maurizio Cutolo, Marieke M. ter Wee	9
4	Changes in body weight and body composition in patients with active rheumatoid arthritis aged 65+ treated with 2-year low-dose add-on prednisolone in the randomised double-blind placebo-controlled GLORIA trial 2023 ·RMD Open ·Melek Güler-Yüksel, T. Martijn Kuijper, Reinhard Bos, Esmeralda T. H. Molenaar, Jasper Emmering, (unknown), (unknown), (unknown), Maarten Boers, Marc R. Kok	3
5	Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial 2022 ·Annals of the Rheumatic Diseases ·Maarten Boers, Linda Hartman, Daniela Opriș-Belinski, Reinhard Bos, Marc R. Kok, José António Pereira da Silva, Eduard N. Griep, Ruth Klaasen, Cornelia F Allaart, Paul Baudoin, Hennie G. Raterman, Zoltán Szekanecz, Frank Buttgereit, P. Masaryk, (unknown), Sabrina Paolino, (unknown), Willem F. Lems, Maurizio Cutolo, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	83
6	Optical imaging compared to clinical examination in 484 rheumatoid arthritis patients: the Leeuwarden Handscan Registry 2022 ·Rheumatology International ·(unknown), (unknown), Nic J.G.M. Veeger, Sytske Anne Bergstra, Dan Zhang, Arno R. Bourgonje, (unknown), (unknown), (unknown), F. Wink, (unknown), T. Huizinga, Reinhard Bos	3
7	[18F]Sodium Fluoride PET has the potential to identify active formation of calcinosis cutis in limited cutaneous systemic sclerosis 2022 ·Seminars in Arthritis and Rheumatism ·(unknown), (unknown), (unknown), Karina de Leeuw, Marc Bijl, Reinhard Bos, Johanna Westra, Harry van Goor, (unknown), (unknown), Douwe J. Mulder	2
8	Medication adherence in older people with rheumatoid arthritis is lower according to electronic monitoring than according to pill count 2021 ·Lara D. Veeken ·Linda Hartman, Maurizio Cutolo, Reinhard Bos, Daniela Opriș-Belinski, Marc R. Kok, (unknown), Ruth Klaasen, Cornelia F Allaart, George A. W. Bruyn, Hennie G. Raterman, Marieke Voshaar, Nuno Gomes, Rui M. A. Pinto, (unknown), Willem F. Lems, Maarten Boers	7
9	Extraskeletal Manifestations in Axial Spondyloarthritis Are Associated With Worse Clinical Outcomes Despite the Use of Tumor Necrosis Factor Inhibitor Therapy 2021 ·The Journal of Rheumatology ·(unknown), Suzanne Arends, (unknown), Reinhard Bos, Hendrika Bootsma, F. Wink, Anneke Spoorenberg	6
10	Intravenous pegylated liposomal prednisolone outperforms intramuscular methylprednisolone in treating rheumatoid arthritis flares: A randomized controlled clinical trial 2021 ·Journal of Controlled Release ·Josbert M. Metselaar, (unknown), Cornelis H. Wortel, Reinhard Bos, Jacob M. van Laar, Harald E. Vonkeman, René Westhovens, Twan Lammers, Siu‐Long Yao, (unknown), (unknown), J. W. J. Bijlsma	19
11	Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial 2020 ·Trials ·(unknown), Paco M J Welsing, Maria J. H. de Hair, Johannes W. G. Jacobs, A.C. Marijnissen, Suzanne P. Linn-Rasker, (unknown), Reinhard Bos, Janneke Tekstra, Jacob M. van Laar	3
12	Ankylosing spondylitis patients at risk of poor radiographic outcome show diminishing spinal radiographic progression during long-term treatment with TNF-α inhibitors 2017 ·PLoS ONE ·F. Maas, Suzanne Arends, F. Wink, Reinhard Bos, Hendrika Bootsma, Elisabeth Brouwer, Anneke Spoorenberg	30
13	Higher Bone Turnover Is Related to Spinal Radiographic Damage and Low Bone Mineral Density in Ankylosing Spondylitis Patients with Active Disease: A Cross-Sectional Analysis 2014 ·PLoS ONE ·Suzanne Arends, Anneke Spoorenberg, M. Efdé, Reinhard Bos, M. K. Leijsma, Hendrika Bootsma, Nic J.G.M. Veeger, Elisabeth Brouwer, E. van der Veer	22
14	The effect of three years of TNF alpha blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study 2012 ·Arthritis Research & Therapy ·Suzanne Arends, Anneke Spoorenberg, P. M. Houtman, M. K. Leijsma, Reinhard Bos, Cees G. M. Kallenberg, Henk Groen, Elisabeth Brouwer, E. van der Veer	41
15	Measurable regression of systemic light chain (AL) amyloid in fat tissue after a response of amyloidogenic free light chain in serum 2011 ·Amyloid ·Ingrid I. van Gameren, Johan Bijzet, Reinhard Bos, P. C. Limburg, Edo Vellenga, Bouke P. C. Hazenberg	1
16	Diagnostic performance of measuring free light chains in fat tissue of patients with AL amyloidosis 2011 ·Amyloid ·Johan Bijzet, Ingrid I. van Gameren, P. C. Limburg, Reinhard Bos, Edo Vellenga, Bouke P. C. Hazenberg	1
17	Diagnostic performance of transthyretin measurement in fat tissue of patients with ATTR amyloidosis 2011 ·Amyloid ·Bouke P. C. Hazenberg, (unknown), Johan Bijzet, P. C. Limburg, Reinhard Bos, E. B. Haagsma	5
18	Regulation of Cytokine‐Induced HIF‐1α Expression in Rheumatoid Synovial Fibroblasts 2007 ·Annals of the New York Academy of Sciences ·Johanna Westra, Elisabeth Brouwer, Reinhard Bos, Marcel D. Posthumus, Berber Doornbos‐van der Meer, Cees G. M. Kallenberg, Pieter C. Limburg	83
19	No Amplifications of Hypoxia‐Inducible Factor‐1α Gene in Invasive Breast Cancer: A Tissue Microarray Study 2004 ·Analytical Cellular Pathology ·M M Vleugel, Reinhard Bos, Horst Buerger, Petra van der Groep, Outi R. Saramäki, Tapio Visakorpi, Elsken van der Wall, P. J. van Diest	21
20	Levels of Hypoxia-Inducible Factor-1 During Breast Carcinogenesis breakdown → 2001 ·JNCI Journal of the National Cancer Institute ·Reinhard Bos, Haining Zhong, Colleen F. Hanrahan, Ellen C.M. Mommers, Gregg L. Semenza, Herbert M. Pinedo, Martin D. Abeloff, Jonathan W. Simons, P. J. van Diest, Elsken van der Wall	508

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact